Objective To study the correlation between class HI p-tubulin expression and efficacy of tubulin-binding-based chemotherapy in advanced non-small cell lung cancer ( NSCLC). Methods One hundred and twenty HIB/IV stage NSCLC patients were enrolled from January 2002 to December 2006. Expression of class HI p-tubulin was examined immunohistochemically in tumor samples obtained by bronchoscopy or lung puncture before treatment. All the patients were treated with 4 to 6 cycles of chemotherapy (taxane/cisplatin or vinorelbine/cisplatin regimen). Overall survival (OS) , time to progression (TTP) and response rate (RR) were assessed after chemotherapy. Results Fifty-three patients finished the trail and could be evaluated. RR, TTP and OS of high expression of class 1 p-tubulin group( n = 31) were 9. 4% , (170. 06 ± 71.45 ) days and (277. 26 ± 112. 82) days, lower than 45. 5% , (289. 45 ± 129. 78) days and (457. 32 ± 207. 12) days of low expression of class H p-tubulin group ( n = 22 ) , respectively (P < 0.001). The expression of class M p-tubulin had no correlation with age, gender, smoking, basic diseases, pathology, complications , family history and PS score. Conclusion The expression of class M P-tubulin has correlation with the sensibility of tubuling-binding chemotherapy, and patients of low expression have longer TTP and OS than patients of high expression. Class IH p-tubulin has no correlation with clinical characteristics in patients with advanced NSCLC.%目的 探讨进展期非小细胞肺癌(NSCLC)组织β微管蛋白Ⅲ(β-tubulinⅢ)的表达情况及其与含微管蛋白结合类化疗药物敏感性之间的关系.方法 收集2002年1月至2006年12月经病理组织学检查确诊的Ⅲ B、Ⅳ期NSCLC初治患者120例,采用免疫组化法检测活检癌组织中β-tubulinⅢ的表达.所有患者行4～6个周期异长春花碱或紫杉类联合顺铂化疗,评价治疗有效率(RR),随访总生存时间(OS)和肿瘤进展时间(TTP),分析上述指标以及临床特征与β-tubulinⅢ表达之间的关系.结果 53例患者均可评价疗效.β -tubulinⅢ高表达者(n=31)的RR、OS、TTP分别为9.4％、(277.26±112.82)天和(170.06 ±71.45)天,均显著低于β-tubulinⅢ低表达者(n=22)的45.5％、(457.32±207.12)天和(289.45±129.78)天(P＜0.001).β-tubulin Ⅲ表达与性别、年龄、病理类型、吸烟情况、TNM分期、基础疾病情况、合并症、癌症家族史、PS评分等临床病理特征均无关.结论 进展期NSCLC的β-tubulin Ⅲ表达情况可能与接受微管蛋白结合类化疗药物的敏感性有关,低表达者疗效及预后均优于高表达者.β-tubulin Ⅲ表达与临床病理特征无关.
展开▼
